Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm
He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Off-Target Effects with Matt Gline
Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term
Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top
Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year
Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries
Get summaries like this every morning.
Free AI-powered recaps of Off-Target Effects with Matt Gline and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.